perivascular epithelioid cell tumors (PEComa)

Parachute

Biotech

Gilead's Immunomedics CMO exits to Aadi as it nears FDA decision

She got Trodelvy to the finish line and now Loretta Itri, M.D., hopes to get Aadi Bioscience's first drug to market.

Kyle LaHucik Oct 25, 2021 9:26am

Money

Celgene-backed Aadi in the driving seat with $23M Series A round

May 8, 2017 8:27am